Supplementary Information for:

Bimodal Accurate H₂O₂ Regulation to Equalize Tumor-Associated Macrophage Repolarization and Immunogenic Tumor Cell Death Elicitation

Yan Zhao^a, Weiheng Kong^a, Jianqing Zhu^c, Fengli Qu*^b

^a College of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, Shandong 273165, China

^b Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang

310022, China

^c Department of Gynecologic Oncology, University Cancer Hospital of Chinese Science Academy, Hangzhou, Zhejiang 310004, China



Figure S1. Population changes of RAW264.7 M1 (CD80^{high}CD206^{low}) macrophages after different concentrations of H_2O_2 incubation.



Figure S2. Apoptosis/necrosis of 4T1 cells treated with different concentrations of (a) H_2O_2 or (b) •OH. (c) Schematic diagram showing apoptosis/necrosis of 4T1 cells after different stimuli.



Figure S3. TEM images of (a) ZnO₂ and (b) Zn-ATM.



Figure S4. (a) DLS of corresponding nanoparticles dispersed in water. (b) DLS size of ZnO_2 -ATM dispersed in water for various times.



Figure S5. XPS survey spectrum of ZnO₂; inset shows O 1s XPS spectrum of ZnO₂.



Figure S6. TEM image of ZnO₂-ATM after 24 h of incubation at pH 5.0.



Figure S7. Zn²⁺ release from (a) ZnO₂ or (b) Zn-ATM after incubation with different solution conditions.



Figure S8. Zn^{2+} release from corresponding nanoparticles after incubation with the emulated tumor environment (pH = 5.0, GSH: 5 mM; ATP: 200 µg/mL) and the emulated immune environment (ATP: 200 µg/mL).



Figure S9. The kinetic spectroscopies of •OH generation of ZnO_2 -ATM + HRP after incubation with the emulated tumor environment (pH = 5.0, GSH: 5 mM; ATP: 200 µg/mL) and the emulated immune environment (ATP: 200 µg/mL).



Figure S10. (a) O_2 generation of $H_2O_2 + CAT$ in the presence of ATM or not. (b) O_2 generation of $H_2O_2 + CAT$ in the presence of corresponding nanoparticles.



Figure S11. Cell viability of 4T1 cells incubated with different concentrations of corresponding nanoparticles (quantification by ATM).



Figure S12. (a) Confocal images of JC-1 staining after various treatments (green: monomer; red: aggregates; blue: nuclear). (b) Quantification of Green/Red intensity after various treatments.



Figure S13. Population changes of M1 (CD80^{high}CD206^{low}) RAW264.7 macrophages after LPS or IL-4 incubation.



Figure S14. Average primary tumor weights from different treatment groups at 14 days post-injection.



Figure S15. Average body weight curves of mice of different groups recorded after different treatments.



Figure S16. H&E-stained organ slices at 14 days post-injection of corresponding treatments.



Figure S17. H&E-stained primary tumor slices at 1-day post-injection.



Figure S18 TUNEL immunofluorescence (blue: nucleus; green: apoptosis) of primary tumor slices at 1 day postinjection.



Figure S19. CRT immunofluorescence (blue: nucleus; red: CRT) of primary tumor slices at 1 day post-injection.



Figure S20. (a) IL-6 and (b) TNF-α of primary tumor at 3 days post-injection.



Figure S21. T-cell infiltration of primary tumors under different treatment groups at 3 days post-injection.



Figure S22. T-cell infiltration of distant tumors under different treatment groups at 14 days post-injection.



Figure S23. (a) H&E-stained distant tumor slices at 14 days post-injection. (b) TUNEL immuno-fluorescence (blue: nucleus; green: apoptosis) of distant tumor slices at 14 days post-injection.



Figure S24. Memory T-cell production in the spleen under different treatment groups at 20 days post-injection.



Figure S25. Lung metastasis model construction.



Figure S26. Survival rate of mice under different treatment groups.



Figure S27. H&E-stained lung sections at 44 days post-injection. Red arrows indicate metastases.